BioDelivery Sciences has completed enrollment of it Phase III study of clonidine topical gel for the treatment of painful diabetic neuropathy (PDN). "We are very pleased with the rapid progression of this study, which we expect will allow for an independent interim analysis based on 50% of the patients completed during the third quarter of this year--one quarter ahead of schedule," Dr. Andrew Finn, executive vice president of product development, said in a statement. "The expeditious enrollment of this study in part illustrates the significant unmet need that exists for new treatment options for patients suffering from painful diabetic neuropathy. Based on the enrollment of this trial, and assuming no additional patients will be required following the interim analysis, we should have top-line study results by the end of the year." Release